Shire/TKT Merger Deal Focuses On Dynepo Rights In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire will promote TKT's Dynepo in Europe with part of its 200-person Fosrenol sales force. European rights to the erythropoietin product were one of the critical components to the $1.6 bil. acquisition. The deal also brings Shire two products in development.
You may also be interested in...
Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
Replagal Advisory Committee Will Include Closed Door Session On Manufacturing
FDA’s Cardiovascular and Renal Drugs Advisory Committee will assess Shire biologics’ BLA for the Fabry disease therapy, which already is available in the U.S. due to shortages of competitor Fabrazyme, during a March 27 meeting.
TKT’s Former CEO Settles SEC Fraud Charges For $1.2 Million
Charges date to 2005 for misleading statements made about Replagal; Transkaryotic Therapies was later acquired by Shire.